Regeneron and Teva Provide Update on Fasinumab Clinical Development Programs
Teva Pharmaceuticals | October 17, 2016
JERUSALEM & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Oct. 17, 2016-- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today provided an update on fasinumab, triggered by a recent development in a Phase 2b fasinumab study in patients with chronic low back pain.